bioAffinity Technologies, Inc. Annual Report - A Look Back at 2025

Welcome to our plain-language summary of bioAffinity Technologies, Inc.'s performance in 2025. We'll cut through the financial jargon to explain what the company does, how it performed this past year, and what its future might hold. Our goal is to provide you with a clear, accessible overview of their latest annual filing.

Here's a detailed look at bioAffinity Technologies' performance and outlook for 2025:

1. What bioAffinity Technologies Does and How It Performed This Year

• What They Do: bioAffinity Technologies is a biotechnology company developing new medical products. They focus on creating and selling non-invasive diagnostic tests and potential treatments. Their main product, CyPath® Lung, is a non-invasive test that uses advanced cell analysis to help detect lung cancer early. The company also explores other diagnostic and therapeutic uses for its technology.
• How They Performed in 2025: The year 2025 was crucial for bioAffinity. The company began its first commercial sales efforts for CyPath® Lung and continued to invest in research and development. While revenue generation started, the company primarily focused on expanding its market presence and advancing its product pipeline. Operationally, diagnostic test volumes increased, though modestly, suggesting early market acceptance. bioAffinity allocated significant resources to sales, marketing, and ongoing clinical studies to validate its product.

2. Financial Performance: Revenue, Profit, and Growth

• Market Snapshot: As of December 31, 2025, bioAffinity Technologies' total value of outstanding shares (market capitalization) was approximately $22.6 million, with about 4.5 million shares of common stock in circulation. The stock price moved throughout the year, reflecting investor sentiment toward early-stage biotech companies and specific company milestones.
• Revenue: For the fiscal year ending December 31, 2025, bioAffinity Technologies reported total revenue of approximately $1.2 million. This revenue primarily came from initial sales and service fees for CyPath® Lung, along with histology service fees and medical director fees. This marks a 150% increase from the prior year's revenue of $0.48 million, showing early commercial momentum.
• Profit/Loss: Despite revenue growth, the company reported a net loss of approximately $12.5 million for 2025, compared to a net loss of $10.1 million in 2024. This increased loss primarily stems from substantial investments in research and development to expand its product pipeline, as well as higher selling, general, and administrative expenses to support CyPath® Lung's commercial launch and market development.
• Earnings Per Share (EPS): The diluted loss per share for 2025 was ($2.78), compared to ($2.25) in 2024.

3. Major Achievements and Challenges This Year

• Major Achievements:
  • Initial Commercial Launch of CyPath® Lung: The company successfully introduced CyPath® Lung into select markets, securing initial contracts and generating its first revenue.
  • Positive Clinical Data: bioAffinity continued to gather and present positive real-world evidence and clinical validation data, reinforcing CyPath® Lung's effectiveness in early lung cancer detection.
  • Strategic Partnerships: The company formed key partnerships with diagnostic labs and healthcare providers to broaden CyPath® Lung's reach and availability.
• Major Challenges:
  • Significant Cash Use: Operating at a substantial net loss required careful cash management and highlighted the ongoing need for additional funding.
  • Market Adoption Hurdles: Gaining widespread acceptance for a new diagnostic test in a competitive and regulated healthcare market proved challenging, demanding extensive education and sales efforts.
  • Regulatory & Reimbursement: Navigating complex regulatory processes and securing favorable reimbursement policies for CyPath® Lung remained a significant obstacle to commercial expansion.

4. Financial Health: Cash, Debt, and Liquidity

• Cash Position: As of December 31, 2025, bioAffinity Technologies held approximately $3.5 million in cash and cash equivalents. This amount is down from $8.0 million at the end of 2024, reflecting the rate at which the company uses cash for its operations.
• Debt: The company reported minimal long-term debt of approximately $0.5 million, mainly for equipment financing.
• Liquidity: Given its current cash position and ongoing net losses, we estimate the company's cash runway to be approximately 6-9 months without securing additional financing. This indicates a critical need for capital to sustain operations and fund commercialization efforts beyond mid-2026.

5. Key Risks That Could Affect the Stock Price

• Funding Risk: The company's ability to continue operating depends heavily on securing additional capital through stock offerings, debt financing, or strategic partnerships. If it fails to raise enough funds, operations and product development could be significantly impacted.
• Commercialization & Market Acceptance: Despite the initial launch, the company may not achieve widespread adoption and significant revenue from CyPath® Lung. Challenges include physician and patient acceptance, competitive pressures, and securing favorable reimbursement.
• Clinical Trial & Regulatory Risks: Future product candidates and ongoing validation for CyPath® Lung face inherent risks in clinical development, including potential failures, delays, and unexpected costs. Regulatory approvals (e.g., FDA) are crucial, and these processes can be lengthy and uncertain.
• Competition: The lung cancer diagnostic market is highly competitive, with established players and new companies developing alternative diagnostic methods. This competition could limit CyPath® Lung's market share and pricing power.
• Intellectual Property (IP): Protecting its proprietary technology (CyPath® Lung) through patents and trademarks is vital. Any challenges to its IP, or costly legal disputes, could severely impact the business.
• Reliance on Third Parties: The company relies on third-party manufacturers, clinical research organizations, and commercial partners. Disruptions or failures from these partners could negatively affect product supply, clinical trials, or market access.
• Economic & Geopolitical Conditions: Broader economic downturns, inflation, rising interest rates, or geopolitical instability could impact healthcare spending, the availability of investment capital, and supply chains, ultimately affecting the company's financial performance.

6. Competitive Positioning

bioAffinity Technologies aims to position CyPath® Lung as a non-invasive, highly accurate, and cost-effective solution for early lung cancer detection, especially for high-risk individuals. While it competes with traditional methods like CT scans and bronchoscopy, and newer liquid biopsy technologies, CyPath® Lung's unique cell analysis approach offers a distinct advantage in specific clinical situations. However, the market is crowded, and gaining market share requires substantial investment in clinical evidence and outreach to customers.

7. Leadership and Strategy Changes

• Strategy: The company's core strategy for 2025 and beyond focuses on:
  1. Accelerating CyPath® Lung Commercialization: Expanding sales and marketing efforts, securing more contracts, and pursuing broader reimbursement coverage.
  2. Advancing the Pipeline: Continuing research and development for new diagnostic and therapeutic uses of its technology.
  3. Capital Acquisition: Actively seeking additional funding to support operational growth and strategic initiatives.
• Leadership: The company reported no significant changes in executive leadership in 2025, providing continuity in strategic execution. The board of directors remained stable, focusing on governance and the company's long-term vision.

8. Future Outlook

For the coming year (2026), bioAffinity Technologies anticipates continued efforts to drive adoption of CyPath® Lung, aiming for a 50-75% increase in revenue from diagnostic services. They plan to expand their commercial presence into additional states and healthcare systems. Research and development will continue, with potential announcements regarding new product candidates or expanded uses for existing technology. Securing additional capital remains a top priority to ensure sustained growth and operational stability.

9. Market Trends and Regulatory Changes Affecting bioAffinity Technologies

• Increased Focus on Early Cancer Detection: A growing emphasis on preventative care and early diagnosis in cancer treatment, particularly for lung cancer, creates a favorable market for CyPath® Lung.
• Personalized Medicine & Diagnostics: The trend toward personalized medicine supports the adoption of targeted diagnostic tools that can improve patient outcomes.
• Reimbursement Landscape: Changes in healthcare reimbursement policies, especially for new diagnostic tests, could significantly impact market access and profitability. The company is actively working to secure broader coverage and favorable pricing.
• Telehealth & Remote Diagnostics: The ongoing shift toward remote healthcare services could create opportunities for non-invasive, easily deployable diagnostic solutions like CyPath® Lung.